New 52 Week Low Today

PolarityTE Inc PTE:NASDAQ

RT Quote | Last NYSE Arca, VOL From CTA | USD
after hours iconAfter Hours: Last | 05/20/22 EDT
2.52quote price arrow up+0.17 (+7.23%)
Volume
1,150
Close
2.35quote price arrow down-0.51 (-17.83%)
Volume
263,634
52 week range
2.32 - 29.50
Loading...
  • Open2.75
  • Day High2.95
  • Day Low2.32
  • Prev Close2.35
  • 52 Week High29.50
  • 52 Week High Date06/16/21
  • 52 Week Low2.32
  • 52 Week Low Date05/20/22

Key Stats

  • Market Cap9.40M
  • Shares Out4.00M
  • 10 Day Average Volume0.52M
  • Dividend-
  • Dividend Yield-
  • Beta1.21
  • YTD % Change-83.99

KEY STATS

  • Open2.75
  • Day High2.95
  • Day Low2.32
  • Prev Close2.35
  • 52 Week High29.50
  • 52 Week High Date06/16/21
  • 52 Week Low2.32
  • 52 Week Low Date05/20/22
  • Market Cap9.40M
  • Shares Out4.00M
  • 10 Day Average Volume0.52M
  • Dividend-
  • Dividend Yield-
  • Beta1.21
  • YTD % Change-83.99

RATIOS/PROFITABILITY

  • EPS (TTM)-5.04
  • P/E (TTM)-0.47
  • Fwd P/E (NTM)-0.38
  • EBITDA (TTM)-31.083M
  • ROE (TTM)-71.74%
  • Revenue (TTM)5.44M
  • Gross Margin (TTM)51.40%
  • Net Margin (TTM)-304.42%
  • Debt To Equity (MRQ)8.87%

EVENTS

  • Earnings Date08/10/2022(est)
  • Ex Div Date01/19/2016
  • Div Amount0.3355
  • Split Date-
  • Split Factor-

Latest On PolarityTE Inc

There is no recent news for this security.

Content From Our Affiliates

There is no recent news for this security.

Profile

MORE
PolarityTE, Inc. is a biotechnology company. The Company is focused on developing regenerative tissue products and biomaterials. It also operates a laboratory testing and clinical research business using equipment, personnel, and facilities it acquired to advance its development of regenerative tissue products. Its first regenerative tissue product is SkinTE, which is intended for the repair, reconstruction, replacement, and supplementation of skin in patients who have a need...
Peter Cohen
Independent Chairman of the Board
Richard Hague
President, Chief Executive Officer
Jacob Patterson
Interim Chief Financial Officer
Cameron Hoyler J.D.
General Counsel, Secretary, Executive Vice President Corporate Development and Strategy
Address
1960 S. 4250 West
Salt Lake City, UT
84104
United States

Top Peers

SYMBOLLASTCHG%CHG
YMTX
Yumanity Therapeutics Inc
1.11-0.03-2.77%
HSTO
Histogen Inc
0.18-0.0087-4.6105%
CBIO
Catalyst Biosciences Inc
0.38UNCHUNCH
PULM
Pulmatrix Inc
4.98-0.19-3.67%
LOGC
LogicBio Therapeutics Inc
0.4374+0.0087+2.03%